Literature DB >> 8494391

In vitro activities of new macrolides and rifapentine against Brucella spp.

J A García-Rodríguez1, J L Muñoz Bellido, M J Fresnadillo, I Trujillano.   

Abstract

We have tested the in vitro activities of streptomycin, rifampin, tetracyclines, trimethoprim-sulfamethoxazole, erythromycin, four new macrolides (roxithromycin, azithromycin, clarithromycin, and dirithromycin), and rifapentine against 62 strains of Brucella spp. Azithromycin and clarithromycin were, respectively, eight- and twofold more active than erythromycins (MIC for 90% of strains = 2, 8, and 16 micrograms/ml, respectively). The activity of rifapentine was similar to that of rifampin (MIC for 90% of strains = 1 microgram/ml).

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8494391      PMCID： PMC187812          DOI： 10.1128/AAC.37.4.911

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  Lack of effective bactericidal activity of new quinolones against Brucella spp.

Authors:  J A García-Rodriguez; J E García Sánchez; I Trujillano
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

Review 2.  New directions for macrolide antibiotics: structural modifications and in vitro activity.

Authors:  H A Kirst; G D Sides
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

3.  Multicenter prospective study of treatment of Brucella melitensis brucellosis with doxycycline for 6 weeks plus streptomycin for 2 weeks.

Authors:  J M Cisneros; P Viciana; J Colmenero; J Pachón; C Martinez; A Alarcón
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

Review 4.  Review of pulmonary brucellosis: a case report on brucellar pulmonary empyema.

Authors:  J A García-Rodriguez; J E García-Sánchez; J L Muñoz Bellido; V Ortiz de la Tabla; J Bellido Barbero
Journal:  Diagn Microbiol Infect Dis       Date:  1988-09       Impact factor: 2.803

5.  Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis.

Authors:  L B Heifets; P J Lindholm-Levy; M A Flory
Journal:  Am Rev Respir Dis       Date:  1990-03

6.  Intracellular accumulation of azithromycin by cultured human fibroblasts.

Authors:  R P Gladue; M E Snider
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

7.  Comparative trial of doxycycline plus streptomycin versus doxycycline plus rifampin for the therapy of human brucellosis.

Authors:  J D Colmenero Castillo; S Hernandez Marquez; J M Reguera Iglesias; F Cabrera Franquelo; F Rius Diaz; A Alonso
Journal:  Chemotherapy       Date:  1989       Impact factor: 2.544

8.  Effect of ciprofloxacin on intracellular organisms: in-vitro and in-vivo studies.

Authors:  C S Easmon; J P Crane; A Blowers
Journal:  J Antimicrob Chemother       Date:  1986-11       Impact factor: 5.790

9.  Uptake and activity of rifapentine in human peritoneal macrophages and polymorphonuclear leukocytes.

Authors:  A Pascual; D Tsukayama; J Kovarik; G Gekker; P Peterson
Journal:  Eur J Clin Microbiol       Date:  1987-04       Impact factor: 3.267

Review 10.  New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy.

Authors:  H A Kirst; G D Sides
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191
View more
  9 in total

Review 1.  Use of aminoglycosides in treatment of infections due to intracellular bacteria.

Authors:  M Maurin; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

2.  In vitro activity of nonsteroidal anti-inflammatory agents, phenotiazines, and antidepressants against Brucella species.

Authors:  S Muñoz-Criado; J L Muñoz-Bellido; J A García-Rodríguez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-05       Impact factor: 3.267

3.  Broth microdilution susceptibility testing of Brucella species: quality control limits for ten antimicrobial agents against three standard quality control strains.

Authors:  Steven D Brown; Maria M Traczewski
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

Review 4.  Recognition and optimum treatment of brucellosis.

Authors:  J Solera; E Martínez-Alfaro; A Espinosa
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

Review 5.  Rifapentine.

Authors:  B Jarvis; H M Lamb
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

Review 6.  Dirithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  R N Brogden; D H Peters
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

7.  In vitro antibiotic susceptibility testing of Brucella isolates from Egypt between 1999 and 2007 and evidence of probable rifampin resistance.

Authors:  Mohamed Abdel-Maksoud; Brent House; Momtaz Wasfy; Bassem Abdel-Rahman; Guillermo Pimentel; Gehan Roushdy; Erica Dueger
Journal:  Ann Clin Microbiol Antimicrob       Date:  2012-08-28       Impact factor: 3.944

8.  In vitro synergistic activity of antibiotic combinations against Brucella melitensis using E-test methodology.

Authors:  Selcuk Kilic; Murat Dizbay; Kenan Hizel; Dilek Arman
Journal:  Braz J Microbiol       Date:  2008-06-01       Impact factor: 2.476

9.  Tulathromycin treatment does not affect bacterial dissemination or clearance of Brucella melitensis 16M following experimental infection of goats.

Authors:  Paola M Boggiatto; Steven C Olsen
Journal:  PLoS One       Date:  2019-12-10       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.